+Compare
EVAX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
24.01M

EVAX Price Prediction, Evaxion Biotech A/S American Depositary Share AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EVAX with price predictions
07:00 PM EST Nov 26, 2023

Momentum Indicator for EVAX turns positive, indicating new upward trend

EVAX saw its Momentum Indicator move above the 0 level on November 24, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator turned positive. In of the 46 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EVAX advanced for three days, in of 117 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EVAX moved out of overbought territory on November 08, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for EVAX turned negative on November 09, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at .

EVAX moved below its 50-day moving average on November 27, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EVAX crossed bearishly below the 50-day moving average on November 20, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EVAX broke above its upper Bollinger Band on October 31, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.811) is normal, around the industry mean (20.463). P/E Ratio (0.000) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.780).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I. Advisor
published Earnings

EVAX is expected to report earnings to fall 7.14% to -19 cents per share on November 27

Evaxion Biotech A/S American Depositary Share EVAX Stock Earnings Reports
Q3'23
Est.
$-0.19
Q2'23
Beat
by $0.01
Q1'23
Beat
by $0.02
Q4'22
Missed
by $0.03
Q3'22
Beat
by $0.03
The last earnings report on August 18 showed earnings per share of -20 cents, beating the estimate of -21 cents. With 17.32K shares outstanding, the current market capitalization sits at 24.01M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 467.58B. NVO holds the highest valuation in this group at 467.58B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 7%. SEPSF experienced the highest price growth at 145%, while TMBR experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Dr. Neergaards Vej 5f
Phone
+45 53531850
Employees
63
Web
https://www.evaxion-biotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASAI13.660.09
+0.66%
Sendas Distribuidora SA
RETO0.60N/A
-0.17%
ReTo Eco-Solutions
BHE25.34-0.08
-0.31%
Benchmark Electronics
HAL37.69-0.37
-0.97%
Halliburton Company
BPRN32.65-0.40
-1.21%
Princeton Bancorp

EVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVAX has been loosely correlated with ATRA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EVAX jumps, then ATRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVAX
1D Price
Change %
EVAX100%
-5.80%
ATRA - EVAX
40%
Loosely correlated
-3.22%
IKNA - EVAX
28%
Poorly correlated
+1.90%
NRIX - EVAX
27%
Poorly correlated
-4.50%
SPRB - EVAX
27%
Poorly correlated
-1.41%
ORMP - EVAX
25%
Poorly correlated
+1.38%
More